1. Scrip
  2. >>Business

Biogen Makes Lifecycle Gambit In Next-Gen MS Drug Deal With Alkermes

 
• By Joseph Haas

ALKS 8700 could help Biogen extend its MS franchise beyond Tecfidera. The next-generation fumarate may have better GI tolerability and patent protection into 2033.

Two businessmen shaking hands during a meeting in the office, success, dealing, greeting & business partner concepts - soft light.

Alkermes PLC has signed the most obvious partner for its late-stage multiple sclerosis drug, Biogen Inc., in a deal that seems advantageous to both companies. The Phase III next-generation fumarate ALKS 8700 could offer potential tolerability advantages compared to Biogen's currently marketed Tecfidera (dimethyl fumarate) and importantly is patent protected until 2033.

Thus, the deal announced Nov. 27 appears to be a sensible lifecycle-extension gambit for Biogen if it can successfully differentiate...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

After Gilead Deal, Hookipa Hangs Up Its Hat

 
• By Kevin Grogan

The Austrian firm is delisting from the NASDAQ and closing down.

Genentech Gets Columvi Complete Response Following ODAC’s No

 
• By Joseph Haas

Seeking to move Columvi into second-line DLBCL, Genentech got an FDA letter saying the Phase III STARGLO study’s benefits may have been driven by results in Asian enrollees.

Novartis Chief Warns Of Fewer Launches And Drug Withdrawals In Europe

 
• By Kevin Grogan

Reimbursement rules are disincentivizing innovation, according to Vas Narasimhan.